LB Pharmaceuticals Inc Common Stock (LBRX) 10-Year Financial Performance & Capital Metrics

LBRX • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutClinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.Show more

Revenue $0
EBITDA -$65M -469.3%
Net Income -$63M -905.6%
EPS (Diluted) -17.83 -907.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-79.41%

5Y Avg-79.41%

3Y Avg-79.41%

Latest-189.35%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0
Revenue Growth %	-	-	-
Cost of Goods Sold+	0	0	0
COGS % of Revenue	-	-	-
Gross Profit+	0	0	0
Gross Margin %	-	-	-
Gross Profit Growth %	-	-	-
Operating Expenses+	2.81M	11.38M	64.83M
OpEx % of Revenue	-	-	-
Selling, General & Admin	1.46M	3.53M	13.66M
SG&A % of Revenue	-	-	-
Research & Development	1.35M	7.84M	51.17M
R&D % of Revenue	-	-	-
Other Operating Expenses	0	0	0
Operating Income+	-2.81M	-11.38M	-64.83M
Operating Margin %	-	-	-
Operating Income Growth %	-	-3.05%	-4.7%
EBITDA+	-2.81M	-11.37M	-64.74M
EBITDA Margin %	-	-	-
EBITDA Growth %	-	-3.05%	-4.69%
D&A (Non-Cash Add-back)	2K	4K	91K
EBIT	-12.2M	-1.45M	-63.1M
Net Interest Income+	-2.08M	-4.01M	1.72M
Interest Income	73K	811K	1.72M
Interest Expense	2.15M	4.83M	0
Other Income/Expense	-11.54M	5.1M	1.73M
Pretax Income+	-14.35M	-6.27M	-63.1M
Pretax Margin %	-	-	-
Income Tax+	1K	1K	1K
Effective Tax Rate %	1%	1%	1%
Net Income+	-14.35M	-6.28M	-63.1M
Net Margin %	-	-	-
Net Income Growth %	-	0.56%	-9.06%
Net Income (Continuing)	-14.35M	-6.28M	-63.1M
Discontinued Operations	0	0	0
Minority Interest	0	0	0
EPS (Diluted)+	-4.05	-1.77	-17.83
EPS Growth %	-	0.56%	-9.07%
EPS (Basic)	-4.05	-1.77	-17.83
Diluted Shares Outstanding	3.54M	3.54M	3.54M
Basic Shares Outstanding	3.54M	3.54M	3.54M
Dividend Payout Ratio	-	-	-

Balance Sheet

	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	21.49M	45.63M	28.88M
Cash & Short-Term Investments	21.4M	43.29M	28M
Cash Only	21.4M	14.98M	22.98M
Short-Term Investments	0	28.31M	5.02M
Accounts Receivable	0	0	0
Days Sales Outstanding	-	-	-
Inventory	0	0	0
Days Inventory Outstanding	-	-	-
Other Current Assets	9K	26K	132K
Total Non-Current Assets+	3K	23K	4.66M
Property, Plant & Equipment	3K	23K	4.16M
Fixed Asset Turnover	-	-	-
Goodwill	0	0	0
Intangible Assets	0	0	0
Long-Term Investments	0	0	0
Other Non-Current Assets	0	0	498K
Total Assets+	21.49M	45.66M	33.53M
Asset Turnover	-	-	-
Asset Growth %	-	1.12%	-0.27%
Total Current Liabilities+	469K	2.61M	8.11M
Accounts Payable	156K	1.39M	2.32M
Days Payables Outstanding	-	-	-
Short-Term Debt	0	0	0
Deferred Revenue (Current)	0	0	0
Other Current Liabilities	221K	798K	2.24M
Current Ratio	45.82x	17.51x	3.56x
Quick Ratio	45.82x	17.51x	3.56x
Cash Conversion Cycle	-	-	-
Total Non-Current Liabilities+	49.84M	77.52M	119.98M
Long-Term Debt	24.15M	0	0
Capital Lease Obligations	0	0	3.22M
Deferred Tax Liabilities	0	0	0
Other Non-Current Liabilities	25.69M	77.52M	116.76M
Total Liabilities	50.3M	80.13M	128.09M
Total Debt+	24.15M	0	3.7M
Net Debt	2.74M	-14.98M	-19.27M
Debt / Equity	-	-	-
Debt / EBITDA	-	-	-
Net Debt / EBITDA	-	-	-
Interest Coverage	-1.31x	-2.36x	-
Total Equity+	-28.81M	-34.47M	-94.55M
Equity Growth %	-	-0.2%	-1.74%
Book Value per Share	-8.14	-9.74	-26.71
Total Shareholders' Equity	-28.81M	-34.47M	-94.55M
Common Stock	1K	1K	1K
Retained Earnings	-34.95M	-41.22M	-104.32M
Treasury Stock	0	0	0
Accumulated OCI	0	274K	111K
Minority Interest	0	0	0

Cash Flow

	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.73M	-12.09M	-53.05M
Operating CF Margin %	-	-	-
Operating CF Growth %	-	-3.43%	-3.39%
Net Income	-14.35M	-6.28M	-63.1M
Depreciation & Amortization	2K	4K	91K
Stock-Based Compensation	431K	295K	3.16M
Deferred Taxes	0	0	0
Other Non-Cash Items	11.1M	-4.8M	3.48M
Working Capital Changes	86K	-1.31M	3.31M
Change in Receivables	0	-154K	114K
Change in Inventory	0	0	0
Change in Payables	0	0	0
Cash from Investing+	123K	-28.01M	23.23M
Capital Expenditures	0	-25K	-769K
CapEx % of Revenue	-	-	-
Acquisitions	-	-	-
Investments	-	-	-
Other Investing	0	0	0
Cash from Financing+	22.96M	33.68M	38.31M
Debt Issued (Net)	-	-	-
Equity Issued (Net)	-	-	-
Dividends Paid	0	0	0
Share Repurchases	-	-	-
Other Financing	-2.95M	-2.05M	-1.69M
Net Change in Cash	-	-	-
Free Cash Flow+	-2.73M	-12.12M	-53.82M
FCF Margin %	-	-	-
FCF Growth %	-	-3.44%	-3.44%
FCF per Share	-0.77	-3.42	-15.21
FCF Conversion (FCF/Net Income)	0.19x	1.93x	0.84x
Interest Paid	0	1.98M	0
Taxes Paid	1K	1K	1K

Key Ratios

Metric	2022	2023	2024
Interest Coverage	-1.31x	-2.36x	-
FCF Conversion	0.19x	1.93x	0.84x

Frequently Asked Questions

Growth & Financials

LB Pharmaceuticals Inc Common Stock (LBRX) grew revenue by 0.0% over the past year. Growth has been modest.

LB Pharmaceuticals Inc Common Stock (LBRX) reported a net loss of $63.1M for fiscal year 2024.

Dividend & Returns

LB Pharmaceuticals Inc Common Stock (LBRX) had negative free cash flow of $53.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener